Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma

• Verfasst von: Kumar, Rahul [VerfasserIn]
• Verfasst von: Deng, Maximilian [VerfasserIn]
• Verfasst von: Kool, Marcel [VerfasserIn]
• Verfasst von: Wesseling, Pieter [VerfasserIn]
• Verfasst von: Ryzhova, Marina [VerfasserIn]
• Verfasst von: Zheludkova, Olga [VerfasserIn]
• Verfasst von: Golanov, Andrey V. [VerfasserIn]
• Verfasst von: McLendon, Roger E. [VerfasserIn]
• Verfasst von: Packer, Roger J. [VerfasserIn]
• Verfasst von: Dunham, Christopher [VerfasserIn]
• Verfasst von: Hukin, Juliette [VerfasserIn]
• Verfasst von: Fouladi, Maryam [VerfasserIn]
• Verfasst von: Faria, Claudia C. [VerfasserIn]
• Verfasst von: Pimentel, Jose [VerfasserIn]
• Verfasst von: Walter, Andrew W. [VerfasserIn]
• Verfasst von: Jabado, Nada [VerfasserIn]
• Verfasst von: Cho, Yoon-Jae [VerfasserIn]
• Verfasst von: Perreault, Sebastien [VerfasserIn]
• Verfasst von: Croul, Sidney E. [VerfasserIn]
• Verfasst von: Zapotocky, Michal [VerfasserIn]
• Verfasst von: Hawkins, Cynthia [VerfasserIn]
• Verfasst von: Tabori, Uri [VerfasserIn]
• Verfasst von: Taylor, Michael D. [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Verfasst von: Klimo, Paul [VerfasserIn]
• Verfasst von: Boop, Frederick A. [VerfasserIn]
• Verfasst von: Ellison, David W. [VerfasserIn]
• Verfasst von: Merchant, Thomas E. [VerfasserIn]
• Verfasst von: Onar-Thomas, Arzu [VerfasserIn]
• Verfasst von: Korshunov, Andrey [VerfasserIn]
• Verfasst von: Jones, David T. W. [VerfasserIn]
• Verfasst von: Gajjar, Amar [VerfasserIn]
• Verfasst von: Ramaswamy, Vijay [VerfasserIn]
• Verfasst von: Northcott, Paul A. [VerfasserIn]
• Titel: Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma
• Verf.angabe: Rahul Kumar, PhD; Kyle S. Smith, PhD; Maximilian Deng, MD; Colt Terhune, BA; Giles W. Robinson, MD; Brent A. Orr, MD, PhD; Anthony P.Y. Liu, MBBS; Tong Lin, PhD; Catherine A. Billups, MS; Murali Chintagumpala, MD; Daniel C. Bowers, MD; Timothy E. Hassall, MD; Jordan R. Hansford, MD; Dong Anh Khuong-Quang, PhD; John R. Crawford, MD; Anne E. Bendel, MD; Sridharan Gururangan, MD; Kristin Schroeder, MD, MPH; Eric Bouffet, MD; Ute Bartels, MD; Michael J. Fisher, MD; Richard Cohn, MD; Sonia Partap, MD; Stewart J. Kellie, MD; Geoffrey McCowage, MD; Arnold C. Paulino, MD; Stefan Rutkowski, MD; Gudrun Fleischhack, MD; Girish Dhall, MD; Laura J. Klesse, MD, PhD; Sarah Leary, MD; Javad Nazarian, PhD; Marcel Kool, PhD; Pieter Wesseling, MD; Marina Ryzhova, MD; Olga Zheludkova, MD; Andrey V. Golanov, MD; Roger E. McLendon, MD; Roger J. Packer, MD; Christopher Dunham, MD; Juliette Hukin, MB; Maryam Fouladi, MD; Claudia C. Faria, MD; Jose Pimentel, MD; Andrew W. Walter, MD; Nada Jabado, MD, PhD; Yoon-Jae Cho, MD; Sebastien Perreault, MD; Sidney E. Croul, MD; Michal Zapotocky, MD, PhD; Cynthia Hawkins, MD, PhD; Uri Tabori, MD; Michael D. Taylor, MD, PhD; Stefan M. Pfister, MD; Paul Klimo Jr, MD; Frederick A. Boop, MD; David W. Ellison, MD, PhD; Thomas E. Merchant, DO, PhD; Arzu Onar-Thomas, PhD; Andrey Korshunov, MD; David T.W. Jones, PhD; Amar Gajjar, MD; Vijay Ramaswamy, MD, PhD; and Paul A. Northcott, PhD
• E-Jahr: 2021
• Jahr: January 27, 2021
• Umfang: 18 S.
• Fussnoten: Gesehen am 12.05.2021
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2021
• Band/Heft Quelle: 39(2021), 7, Seite 807-821
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.20.01359
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1757728945

Abstract

PURPOSEWe sought to investigate clinical outcomes of relapsed medulloblastoma and to compare molecular features between patient-matched diagnostic and relapsed tumors.METHODSChildren and infants enrolled on either SJMB03 (NCT00085202) or SJYC07 (NCT00602667) trials who experienced medulloblastoma relapse were analyzed for clinical outcomes, including anatomic and temporal patterns of relapse and postrelapse survival. A largely independent, paired molecular cohort was analyzed by DNA methylation array and next-generation sequencing.RESULTSA total of 72 of 329 (22%) SJMB03 and 52 of 79 (66%) SJYC07 patients experienced relapse with significant representation of Group 3 and wingless tumors. Although most patients exhibited some distal disease (79%), 38% of patients with sonic hedgehog tumors experienced isolated local relapse. Time to relapse and postrelapse survival varied by molecular subgroup with longer latencies for patients with Group 4 tumors. Postrelapse radiation therapy among previously nonirradiated SJYC07 patients was associated with long-term survival. Reirradiation was only temporizing for SJMB03 patients. Among 127 patients with patient-matched tumor pairs, 9 (7%) experienced subsequent nonmedulloblastoma CNS malignancies. Subgroup (96%) and subtype (80%) stabilities were largely maintained among the remainder. Rare subgroup divergence was observed from Group 4 to Group 3 tumors, which is coincident with genetic alterations involving MYC, MYCN, and FBXW7. Subgroup-specific patterns of alteration were identified for driver genes and chromosome arms.CONCLUSIONClinical behavior of relapsed medulloblastoma must be contextualized in terms of up-front therapies and molecular classifications. Group 4 tumors exhibit slower biological progression. Utility of radiation at relapse is dependent on patient age and prior treatments. Degree and patterns of molecular conservation at relapse vary by subgroup. Relapse tissue enables verification of molecular targets and identification of occult secondary malignancies.